Xenetic Biosciences, Inc. XBIO
2.37
(0.10)
(4.05%)
as of 25 Sep
- Market cap
- $5.8M
- P/E
- 0.0×
Follow XBIO
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| P/E ratio | 0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
| P/S ratio | 2.05 | 1.92 | 1.24 | 1.69 | |
| P/FCF ratio | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/Operating CF | (7.63) | (11.45) | (15.21) | (7.36) | |
| P/B ratio | 1.10 | 0.88 | 0.50 | 1.22 | |
| Price to Tangible BV | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/Sales | 0.07 | (0.38) | (1.40) | 0.26 | |
| EV/EBITDA | 0.00 | 0.50 | 1.48 | 0.00 | |
| EV/Operating CF | (0.09) | 0.66 | 1.83 | (0.27) | |
| EV/FCF | (0.09) | 0.66 | 1.83 | (0.27) | |
| Quick Ratio | 7.23 | 7.67 | 8.14 | 3.71 | |
| Current Ratio | 7.43 | 7.93 | 8.32 | 4.56 | |
| Net Debt/EBITDA | 6.66 | 14.63 | 12.65 | 7.57 | |
| Debt/Assets | 0.00% | 0.00% | 0.00% | 0.00% | |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover | 0.53 | 0.47 | 0.39 | 0.44 | |
| Operating CF/Net income | 0.94 | 1.18 | 0.42 | 1.29 | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 83.56% | 81.97% | 100.93% | 73.66% | |
| Selling, General and Administrative Expense of Revenue | 163.53% | 80.26% | 80.37% | 79.38% | |
| Intangible Assets out of Total Assets | 0.00 | 0.00 | 0.00 | 0.00 | |
| Share Based Compensation of Revenue | 7.87% | 1.40% | 1.83% | 1.55% | |
| Graham Net Nets | 0.86 | 1.08 | 1.92 | 0.82 | |
| Graham Number | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | (39.86%) | (44.78%) | (73.27%) | (65.29%) | |
| Free Cash Flow Yield | (34.61%) | (29.63%) | (61.87%) | (56.09%) | |
| Revenue per Share | 0.29 | 0.35 | 0.45 | 0.67 | |
| Operating CF per Share | (0.38) | (0.23) | (0.14) | (0.43) | |
| Capex per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow per Share | (0.38) | (0.23) | (0.14) | (0.43) | |
| Cash per Share | 2.82 | 3.21 | 4.63 | 2.67 | |
| Shareholders Equity per Share | 2.65 | 3.03 | 4.35 | 2.57 | |
| Interest Debt per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book value per Share | 2.65 | 3.03 | 4.35 | 2.57 | |
| Free Cash Flow | (0.88) | (0.54) | (0.24) | (0.66) | |
| Working Capital | 5.76 | 6.64 | 7.08 | 3.96 | |
| Net Current Asset Value | 5.76 | 6.64 | 7.08 | 3.96 | |
| EV/EBIT | 0.00 | 0.50 | 1.48 | 0.00 | |
| Capex to Sales | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin | (140.74%) | (56.56%) | (75.57%) | (49.65%) | |
| Price to Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
| Average Payables | 0.33 | 0.40 | 0.27 | 0.41 | |
| Average Assets | 6.16 | 6.85 | 7.63 | 6.56 | |
| Average Common Equity | 5.26 | 6.04 | 6.70 | 5.49 |
Columns are period end dates